Strategic Overview- By establishing a launch leadership team and fostering cross-functional collaboration, a seasonal vaccine manufacturer swiftly launched products globally, achieving $1+ billion in revenue from vaccine sales and enhancing operational efficiency.
Context
- The company specializing in seasonal vaccine production, poised to become a life-saving entity globally
- The emergence of COVID heightened the importance of seasonal vaccine manufacturing, making it a critical component against the pandemic
- With the seasonal nature of respiratory viruses, adapting the product annually became imperative. Operating across 40 countries, the company faced the challenge of tailoring product presentations to suit diverse markets, distribution channels, and financial capacities
- This endeavor demanded close collaboration among regulation, quality, supply chain, operations, marketing, and R&D teams, forming cross-functional units to address the massive geographic scope and fast-paced requirements
Approach:
- The company initiated a launch leadership team with necessary capabilities, governance structures, and reporting tools to manage global scaling complexities
- This included rapid prototyping, clear communication channels, and tools like Smartsheets and governance dashboards to ensure a single source of truth and facilitate quick decision-making from leadership to the shop floor
- Urgency and mission were emphasized, and close collaboration among regulatory, commercial, marketing, and sales teams was prioritized to address unique market needs and challenges
Results:
- The diligent implementation of the approach yielded significant results. The company successfully launched its products in key markets worldwide, including the US, Europe, Japan, and emerging markets, within 24 hours of regulatory approval
- These launches enabled the organization to reach millions of people across diverse geographies and economic conditions, bolstering its position as a critical player in the market
- The company achieved remarkable business objectives, including sales exceeding $1 billion from vaccine revenue, significant reductions in operating costs, and improved inventory turns and volumes
- By entering and performing in a competitive industry environment, demonstrating its capacity for agile and effective global scaling to urgent public health needs
If you have any questions or feedback regarding the case study, feel free to send an email to info@scaleupinc.com. If you wish to know more about ScaleUp and our offerings, please get in touch. You can send an email at mbuelvas@scaleupinc.com
